Preview mode — showing a sample of companies and people. Sign in for full access to emails, LinkedIn profiles, and the complete index.
Sign inInSilico Medicine Hong Kong Limited
- Founded
- 2014
- Team size
- 201-500 (285)
- HQ
- HongKong
- Tech score
- 70 / 100
What they do
The company solves the problem of slow, costly, and unpredictable drug discovery and development by applying generative and predictive artificial intelligence to accelerate target discovery, molecule design, and preclinical-to-clinical advancement (Insilico Medicine, https://insilico.com). - Insilico Medicine uses an end-to-end AI platform called Pharma.AI to link target discovery, biology, and generative chemistry so teams can design novel molecules and progress programs faster. - The platform performs de novo molecule generation, lead optimization, and in silico validation to produce candidate therapeutics and advance them into preclinical and clinical stages. - Insilico demonstrates accelerated development workflows (e.g., taking programs from start to Phase 1 in roughly 30 months) and leverages partnerships and licensing to scale AI-driven R&D across therapeutic areas. Insilico Medicine’s public materials emphasize a mission to extend healthy productive longevity by transforming drug discovery and development with generative AI (Insilico Medicine, https://insilico.com). Their Pharma.AI platform is described as an integrated stack that connects target identification with generative chemistry and predictive biology so that candidates can be rapidly designed, triaged, and progressed into experimental testing. This integrated approach addresses the core industry pain points of long timelines, high attrition, and prohibitive costs. Concrete evidence of the platform’s capabilities is present on the company site: the pipeline pages highlight generative-AI–driven discovery advancing internal programs, and a dedicated case page documents a rapid program progression “From Start to Phase 1 in 30 Months,” showing the platform’s ability to compress discovery and early development timelines. Insilico also publishes news about global R&D collaborations and licensing deals that use their validated AI platform to accelerate partners’ R&D efforts, reinforcing that their systems are built for scalable, industry-grade drug discovery (Insilico Medicine, https://insilico.com).
Key contacts
Emails and LinkedIn profile links sourced from Kuration AI research.
Funding
Score breakdown
70/ 100The company demonstrates strong funding maturity (Series E, 12 rounds) and solid scale (201–500 staff) with clear healthcare AI focus and an identified CEO. However, product maturity is still at Research/Prototype, limiting immediate product-market readiness despite strong financial and organizational indicators.
Research sources
URLs cited by Kuration AI agents when researching this company.
